Status:
COMPLETED
Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III...
Detailed Description
Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III...
Eligibility Criteria
Inclusion
- malignant melanoma stage III/IV
- injectable soft tissue metastasis
- informed consent given
- Karnofsky \>= 70%
Exclusion
- additional chemotherapeutical treatment
- systemic glucocorticoids
- brain metestasis
- other malignancies
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00204594
Start Date
October 1 2005
End Date
December 1 2007
Last Update
January 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tuebingen, Department of dermatology
Tübingen, Germany, 72076